Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1798749 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $20.00Day +3.36%Mkt cap $955M1Y +190.7%Off 52W high −28.5%Vol (1Y) 82.0%
Daily closing price, split-adjusted to the current basis; 1.2y shown of 305 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest15.3% of sh out |
| Days to cover7.2d |
| 13F net flow (QoQ)−0.59% |
| Top-10 13F concentration65.5% |
| Next report (est.)2026-08-07 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Earnings (TTM)-$129.6M |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+29.6% |
| 1Y+190.7% |
| Since incept. (ann.)+72.1% |
Total return through 2026-07-30 · series begins 2025-04-29. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)82.0% |
| Ann. volatility (3Y)87.3% |
| Sharpe (1Y)1.66 |
| Sharpe (3Y)1.09 |
| Max drawdown (1Y)−43.3% |
| Max drawdown (3Y)−45.8% |
| Beta (3Y vs SPY)3.07 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| FMR LLC | 7.1M | $100M | 14.37% | +2.8% |
| Fairmount Funds Management LLC | 4.6M | $64M | 9.23% | +0.0% |
| Avidity Partners Management LP | 2.8M | $54M | 5.68% | +100.0% |
| RA CAPITAL MANAGEMENT, L.P. | 3.7M | $52M | 7.44% | +0.0% |
| Bellevue Group AG | 3.5M | $49M | 7.10% | +4.8% |
| Venrock Adviser, LLC | 3.2M | $45M | 6.53% | +0.0% |
| JANUS HENDERSON GROUP PLC | 3.1M | $44M | 6.30% | new |
| BlackRock, Inc. | 2.3M | $33M | 4.69% | −19.4% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. Institutional 13F holdings sum to 104.2% of shares outstanding. Readings above 100% reflect securities-lending double counting: shares on loan to short sellers are reported long by both the lending institution and the one that bought them. FINRA short interest of 3,097,060 shares (settlement 2026-04-30) accounts for the excess.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-07 | −$0.57 | — | — | — |
| 2025-09-30 | 2025-11-14 | −$0.48 | — | — | — |
| 2025-06-30 | 2025-08-13 | −$0.86 | — | — | — |
| 2025-03-31 | 2025-04-25 | — | — | — | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-07 is ESTIMATED from filing cadence (median gap 92d) — not company-confirmed.
